About iRhythm Technologies, Inc. - Common Stock (IRTC)
Irhythm Technologies Inc is a medical technology company that specializes in the development and commercialization of innovative solutions for cardiac monitoring and arrhythmia detection. The company's flagship product is a wearable ECG monitoring device that allows for continuous heart rhythm assessment, enabling healthcare providers to make more informed decisions regarding patient care. Irhythm aims to improve patient outcomes through its advanced technology, which streamlines the diagnosis and management of various heart conditions, thus enhancing the overall healthcare experience for both patients and providers. Read More
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 8.4%. This drop is a stark contrast from the S&P 500’s 5.4% gain.
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC)
jumped 3.2% in the afternoon session after the positive sentiment from Wall Street analysts who saw further potential in the company. The digital healthcare firm has garnered a "Moderate Buy" consensus rating from analysts. Based on ten recent analyst ratings, the average twelve-month price target for iRhythm sits at $138.60, suggesting potential upside from its current trading level. Nine out of ten of these analysts rate the stock as a "Buy." This bullish stance from market experts likely reflects confidence in iRhythm's Zio service, a platform that uses wearable biosensors and cloud-based data analytics to diagnose cardiac arrhythmias. The company's focus on integrating artificial intelligence to provide clinically actionable insights for physicians positions it well within the growing digital health sector.
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O’Boyle have accepted appointments to the board of directors.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at iRhythm (NASDAQ:IRTC) and its peers.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into iRhythm Technologies, Inc. (NasdaqGS: IRTC).
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Retrospective real-world analyses of patients with type 2 diabetes—some of whom also had chronic kidney disease—demonstrate cardiac arrhythmias present frequent and early, often preceding major cardiovascular events (MACE)
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences.
Exciting developments are taking place for the stocks in this article.
They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 20.3% year on year to $158.7 million. The company’s full-year revenue guidance of $695 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0.96 per share was 2.5% below analysts’ consensus estimates.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 7.5%. This drop was discouraging since the S&P 500 held steady.
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 20.3% year on year to $158.7 million. The company’s full-year revenue guidance of $695 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0.95 per share was 1.5% below analysts’ consensus estimates.
